Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid-induced Constipation Clear all
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00399659
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Timeline
2006 – 2007
U.S. locations
57
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01336205
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Usual care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
169
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

NCT01655771
View directory record Official record
Conditions
Constipation
Interventions
TD-1211 Dose 1, TD-1211 Dose 2
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01323790
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
68
States / cities
Mobile, Alabama • Pell City, Alabama • Mesa, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

NCT01427270
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
170
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

NCT01298219
View directory record Official record
Conditions
Opioid-induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
115
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Not listed Phase 3 Interventional

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

NCT00020605
View directory record Official record
Conditions
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naloxone hydrochloride
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

NCT01418092
View directory record Official record
Conditions
OIC
Interventions
ALKS 37, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Anaheim, California • Orange, California • Daytona Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 2 Interventional

ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)

NCT01100151
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
RDC-1036 (ALKS 37), Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Sheffield, Alabama • Anaheim, California • Pasadena, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 4 Interventional Results available

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

NCT03060512
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
Polyethylene Glycol 3350, Movantik
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
53
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Not applicable Interventional Results available

Compassionate Use Study of Methylnaltrexone

NCT01368562
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00256932
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
alvimopan, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
137
States / cities
Birmingham, Alabama • Calera, Alabama • Muscle Shoals, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00414024
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Timeline
2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

NCT00620061
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone 24
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
120
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

NCT01186770
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
94
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 IV/Oral Mass Balance Study

NCT01702194
View directory record Official record
Conditions
OIC
Interventions
TD-1211 IV [C14], TD-1211 PO [C14]
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

NCT00401362
View directory record Official record
Conditions
Advanced Illness Patients With Opioid Induced Constipation
Interventions
SC Methylnaltrexone, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 4 Interventional

Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients

NCT00799201
View directory record Official record
Conditions
Constipation, Analgesia
Interventions
Naloxone and Docusate
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01309841
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 10, 2026, 4:40 PM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

NCT00595946
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
94
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Terminated Phase 4 Interventional Results available

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

NCT02839889
View directory record Official record
Conditions
Cancer, Constipation, Pain
Interventions
Naloxegol, Placebo
Drug
Lead sponsor
Hospice of Henderson County, Inc.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
New York, New York • Flat Rock, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 10, 2026, 4:40 PM EDT
Not listed No phase listed Observational

Naloxegol US PMR CV Safety.

NCT02813356
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
naloxegol, non-PAMORA
Drug
Lead sponsor
Valinor Pharma LLC
Industry
Eligibility
Not listed
Enrollment
8,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Wilmington, Delaware • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 10, 2026, 4:40 PM EDT